Chapter 28: Principles of Antimicrobial Therapy

Welcome to Last Minute Lecture.

This free chapter overview is designed to help students review and understand key concepts.

These summaries supplement not replaced the original textbook and may not be redistributed or resold.

For complete coverage, always consult the official text.

You know, usually when we talk about treating an illness, there's this expectation of extreme precision.

It feels like taking a tiny pair of tweezers and, I don't know, plucking out a single specific weed from a garden.

Right, which is great in theory, but when you're talking about infectious diseases, the reality is just so much more chaotic.

Yeah, exactly.

Imagine trying to poison a burglar who has broken into your house.

Right.

But the catch is you have to pump a gas into the air vents that will somehow only incapacitate the burglar without harming you, your roommates, or, you know, the family dog.

I mean, it sounds completely impossible.

If you pump a toxin into a closed environment,

it usually just damages everything it touches.

To make that work, the gas has to exploit a vulnerability that only the burglar possesses.

And when we step into the world of infectious disease, that incredibly high stakes scenario is the exact game we are playing every single day in medicine.

Welcome to this special deep dive.

We are so glad you're here.

We are talking directly to you, the college student tackling pharmacology for the very first time.

We know you're staring down this massive mountain of drug names, mechanisms, side effects.

So our goal today is to really shortcut that learning curve.

We're going to translate all that dense material into something that actually makes sense.

Without sacrificing any of the depth you need to ace your exams, of course.

To do that, we're focusing entirely on the foundational principles of antimicrobial therapy, drawing strictly from Chapter 28 of Lippincott Illustrated Reviews, pharmacology.

Right.

We are going to walk through the exact timeline of saving a patient.

From the moment they crash through the emergency room doors, all the way to managing the long term fallout of the drugs themselves.

Okay, let's unpack this.

If the overarching mission is to kill the bug and sick the patient, how do we actually pull off that burglar poisoning trick in the human body?

Well, it all comes down to the core concept of the entire discipline, selective toxicity.

Antimicrobial therapy essentially exploits the biochemical differences that exist between microorganisms and human beings.

So we're looking for biological weak points.

Exactly.

We're looking for structural targets.

Things like specific enzymes, rigid cell walls, or bacterial ribosomes that the bacteria absolutely need to survive, but that human cells either do not have at all or they just have them in a vastly different format.

So we target those microscopic differences to injure the invader while leaving the host's normal cells completely blind to the drug.

Yeah, and what's fascinating here is that this selective toxicity is usually relative, not absolute.

It requires that the concentration of the drug be incredibly carefully controlled.

Because if you overdo it… Right.

You need to deliver enough of the chemical to obliterate the microorganism, but if you push that dose too high, the host's own cells will inevitably start taking collateral damage.

Which means we need to know exactly what we're fighting.

We can't just throw toxic chemicals into the bloodstream blindly.

But let's put this in motion.

Imagine a patient arrives in the ER with severe life -threatening meningitis.

Which is a massive inflammation of the brain and spinal cord.

Very dangerous.

Very.

We need to identify the bug, but we also can't just sit on our hands and wait three days for a lab test to come back while the patient deteriorates.

Yeah, you absolutely can't.

That tension is the defining challenge of the ER.

For acutely ill patients, or for neutropenic patients who just lack the white blood cells needed to fight off infections on their own, a delay in treatment could easily be fatal.

So what do you do?

That brings us to empiric therapy.

You take the laboratory samples immediately, like drawing blood or tapping the spinal fluid, and then you immediately start a broad, aggressive treatment before you actually know what the bug is.

I want to pause on something crucial there.

You draw the samples before you give the drugs.

The textbook emphasizes this golden rule for a very logical reason.

It is so important.

If we pump the patient full of antibiotics first, and then take a swab, that swab might look completely clear under a microscope.

The drug suppresses the bacteria just enough to hide it from the lab culture.

Leaving you totally in the dark about what caused the infection in the first place.

It is a classic clinical pitfall.

You end up not knowing if the lab culture is negative because the patient never actually had an infection,

or because your initial dose of antibiotics just ruined the test.

You always secure the sample first.

Okay, so once that sample is secured, how do we actually make that educated guess for empiric therapy?

I mean, we don't know the bug yet, so what are we basing our drug choice on?

It relies heavily on the site of the infection and the specific history of the patient.

Let's look at the textbook's clinical example regarding that meningitis patient.

If the patient is a newborn baby,

the organism in their spinal fluid is highly unlikely to be streptococcus pneumonia.

Just because of their age.

Right, because of their age and how they were exposed during birth.

It's much more likely to be streptococcus agalaxiae, which is a group B strep.

And that specific bug happens to be beautifully sensitive to a very basic standard drug like penicillin G.

So a newborn gets penicillin G.

But what if the patient rolling into the ER is, say, 40 years old?

That changes the entire landscape.

A 40 -year -old with meningitis is most likely infected with streptococcus pneumonia.

And here's where the history matters.

That organism is frequently resistant to standard penicillin G.

Ah, so the penicillin won't work.

Exactly.

You would likely need to hit it with a high -dose, third -generation cephalosporin, like septriaxone, or even bring out a heavy hitter like vancomycin.

Age alone completely shifts your empiric strategy.

OK, so we've made our educated guess.

The patient is stabilized on empiric therapy, and a few days pass.

The lab has been working on those samples we took on day one.

How does the laboratory actually figure out what the burglar looks like?

The laboratory goes through this visual and chemical cascade of identification.

You can imagine it like a staircase of investigation.

Step one is direct microscopic visualization.

They take that normally sterile fluid, like cerebrospinal fluid, add a gram stain, and physically look through the microscope at the shape and color of the bacteria.

But just looking at their shape isn't always enough to identify the exact species, right?

No, definitely not.

So they move to step two, which is culturing the organism.

They literally grow it out on an agar plate to conclusively identify it.

And if that fails?

If that fails.

Or if the bug is notoriously difficult to grow, they move to step three, detecting microbial antigens.

Step four utilizes rapid techniques like PCR to detect the microbial RNA or DNA itself.

And finally, step five is looking at the host's own immune response by detecting antibodies, seeing what the human body is actively reacting to.

So the dust settles, the lab uses this cascade, and our culture finally grows.

We know the exact identity of the bacteria.

The next logical hurdle is figuring out exactly how much drug is needed to stop it.

We measure its susceptibility.

Right.

To visualize how this works, picture a row of clear test tubes in the lab.

Each tube contains the exact same amount of the patient's bacteria and each contains the antibiotic we want to use.

But the antibiotic concentration changes, right?

Exactly.

It doubles as you go down the line.

Tube one has 0 .5 units, tube two has one unit, then two, four, eight, all the way down.

And you put them in an incubator for 24 hours and then check to see which tubes are cloudy with bacterial growth and which ones are perfectly clear.

Yeah.

The fluid in those lower concentration tubes will be cloudy, meaning the bacteria are thriving despite the drug.

But eventually, you hit a tube where the fluid is clear.

The absolute lowest concentration of antibiotic that prevents that visible growth is called the MIC, the minimum inhibitory concentration.

But you know, just because we can't see the bacteria floating around doesn't mean they're entirely wiped out.

They might just be suppressed, playing dead.

Oh, for sure.

To find out if they are truly dead, the lab takes samples from those clear tubes and physically spreads them onto fresh, drug -free agar plates.

The lowest concentration of the drug that results in a 99 .9 % decline in the bacterial colonies is the MBC, the minimum bactericidal concentration.

This actually brings up a really interesting historical distinction that often trips up students.

Antimicrobials are usually labeled in one of two ways.

They're either bacteriostatic, meaning they just arrest the growth and hit that MIC, or they're bactericidal, meaning they actively kill that 99 .9 % and hit the MBC.

Static for stopping and cital for killing.

Right.

And as a student, my instinct is, why would we ever prescribe a static drug that just freezes the bug if we have a cital drug that drops a bomb on it?

Doesn't cital inherently mean it's a better drug?

It creates an immediate assumption, but it is a massive misconception.

Both types of drugs effectively eliminate organisms in a living patient.

Oh really?

Yeah.

The label bacteriostatic simply means that the drug failed to hit an arbitrary 99 .9 % death rate within an 18 -24 hour window in a glass test tube.

If you track the number of viable bacteria over time, a bactericidal agent like Daptomycin will cause the bacterial count to plummet incredibly fast.

But a bacteriostatic agent like Lenazolid will still cause the bacterial count to drop significantly just on a slightly less steep curve.

So the static drug is still completely capable of curing the infection.

Absolutely.

Furthermore, a single drug can actually be both static and cital depending on the specific bacteria it's facing.

Lenazolid is bacteriostatic against Staphylococcus aureus, but it acts as a purely bactericidal agent against most strains of Streptococcus pneumonia.

That is wild.

Ultimately, whether a drug cures a human being depends far more on getting an adequate concentration of the drug to the physical site of the infection and relying on the strength of the host's own immune system to sweep up the rest of the immobilized bacteria.

Now we have to talk about getting the drug to that physical site.

Getting a drug into a glass test tube in the lab is incredibly easy.

You just use a pipette and drop it in.

But getting a drug into the human brain, that is a physiological fortress.

It really is.

The brain is protected by the blood -brain barrier, or the BBB.

The capillaries inside your brain are not like the leaky capillaries in your arm or your leg.

They are formed by a single layer of endothelial cells fused together by incredibly tight junctions.

It acts as a literal physical wall that protects your central nervous system from circulating toxins.

So if an antibiotic is floating in the bloodstream to melt through that intact BBB, a drug needs three specific biochemical traits.

Okay, what are they?

First, it needs high lipid solubility because it has to physically dissolve through the fat -based cell membranes of the barrier.

Second, it needs a low molecular weight, meaning the drug molecule has to be physically small enough to slip through.

And third, it needs low protein binding.

Let's explore that last one because protein binding is a huge concept in pharmacology.

Why does it matter if a drug binds to a protein?

Well in your bloodstream, many drugs have a chemical affinity to stick to large carrier proteins like albumin, but only the free, unbound portion of the drug can actually squeeze through the tight junctions into the brain fluid.

If a drug is highly protein -bound, it is effectively tethered to a giant boulder.

It remains trapped in the bloodstream and can never reach the brain.

This actually brings us to one of the most fascinating paradoxes in the text.

The irony of inflammation.

Let's take beta -lactam antibiotics like penicillin.

They are ionized at normal physiologic pH and they have very low lipid solubility.

They are basically the exact opposite of what you need to cross the blood -brain barrier.

Under normal, healthy circumstances, penicillin simply cannot enter the brain.

It just bounces right off the barrier.

Right, but if a patient has severe meningitis, their brain is massively inflamed.

And that aggressive inflammation actually breaks down the tight junctions of the blood -brain barrier.

The disease process itself destroys the wall.

Allowing the penicillin to suddenly flood into the brain in therapeutic amounts and kill the bug.

The infection literally provides the key to its own destruction.

It is a remarkable bit of physiological irony.

But getting the drug to the brain is only one patient factor we have to navigate.

As a clinician, you have to run through a systemic checklist of the patient's overall health before writing a prescription.

Oh, absolutely.

We have to look at the body's natural filtration systems.

The kidneys and the liver.

If we are pumping toxic chemicals into the blood, the body is naturally going to try to filter them out.

I imagine if a patient has shot kidneys, that drug is just...

That is exactly what happens.

If a patient has poor renal function,

drugs that are typically cleared by the kidneys will dangerously accumulate.

For heavy -hitting drugs like vancomycin and the amino glycosides, you actually have to institute direct serum monitoring.

Meaning you draw their blood to check the levels.

Exactly.

You draw the patient's blood regularly to check the exact drug levels and ensure they aren't reaching a toxic threshold.

Similarly, if a drug is cleared by the liver, like erythromycin or doxycycline, you must use extreme caution in patients with hepatic dysfunction.

And age is a massive variable too.

We already mentioned the newborn with meningitis needing a different drug just based on the likely bug, but their age also affects how they process the drug.

Yeah, neonates have poorly developed elimination processes in their liver and kidneys.

They simply don't have the machinery fully running yet, making them uniquely vulnerable to the toxic effects of drugs like chloramphenicol.

What about older kids?

Young growing children should absolutely not be treated with tetracyclines because the drug binds to calcium and affects their developing bone growth.

They also shouldn't receive quinolones, which can damage their developing cartilage and joints.

And we can't forget pregnancy.

There's a great study scenario in the book that highlights this.

Imagine a pregnant 24 -year -old presenting with a urinary tract infection.

A standard choice might be a tetracycline like doxycycline, but in this case it must be completely avoided.

Because that drug crosses the placental barrier, it can cause severe congenital abnormalities in the fetus, specifically regarding bone and tooth development.

You are constantly treating two patients, not one.

Wow.

So we've picked a drug that penetrates the right tissues, is safe for the patient's age and organs, and is highly lethal to the bug.

The science is settled.

But pharmacology isn't just biology, it's economics.

We have to consider the cost and the logistics of how we are getting it into their system.

It's refreshing to see the financial cost of health care directly addressed in a pharmacology context.

I mean, efficacy is paramount.

But if two drugs work equally well, cost absolutely must dictate the decision.

The textbook lays out a stark comparison for treating MRSA methicillin -resistant staph aureus.

If you look at figure 28 .4, comparing the cost of the drug cefazolin, it's a tiny, almost negligible sliver on the chart.

But if you look at a drug like daptomycin, the cost is this massive red bar.

It's an exponential leap in price for the patient and the hospital.

Hard of managing that financial burden involves the route of administration, right?

4V versus oral.

Yes.

4V therapy is reserved for critically ill patients requiring incredibly high immediate serum concentrations of the drug.

Or for drugs like vancomycin that have terrible absorption in the GI tract.

If you swallow liquid vancomycin, it essentially just stays in the gut and never reaches the bloodstream.

But once the patient is clinically stable, the goal is always to step down from the IV to an oral pill.

Always.

It saves immense health care costs, it gets the patient out of the expensive hospital and crucially, it eliminates the risk of secondary infections from having an IV capiter just sitting in their vein for weeks.

Whether we are giving it via an IV bag or an oral pill, we have to determine how often to dose the patient.

This brings us to pharmacodynamics.

Bridging how the drug moves through the body with how it actually kills the bacteria.

This is the art of rational dosing, and there are two primary schools of thought here.

Concentration -dependent killing and time -dependent killing.

Let's start with concentration -dependent.

Certain drugs, like the aminoglycosides and Daptomycin, work on a very specific mathematical principle.

The higher the peak concentration, the faster and more aggressive the kill.

In fact, they show a massive increase in bacterial eradication when you push the drug concentration to 4 to 64 -fold higher than the minimum inhibitory concentration.

My favorite analogy for concentration -dependent killing is a lightning strike.

You don't want a steady gentle drizzle of a drug.

You want one massive, overwhelming, daily bolt of electricity.

I love that.

You give a huge bolus infusion once a day, hit an incredibly high peak level in the blood, wipe out the pathogen, and then let the drug levels fall.

That visual perfectly captures it.

Now contrast that lightning strike with time -dependent killing, which applies to the beta -lactams, the macrolides, and clindamycin.

These drugs operate under a completely different logic.

They don't care about the peak.

They do not care how high the peak concentration gets.

Pumping in 64 times the MIC does not kill the bug any faster than just being slightly above the MIC.

So if the peak height of the lightning strike doesn't matter, what does?

The duration of the siege.

Their clinical efficacy is entirely predicted by the percentage of time that the blood concentration of the drug remains above that minimum inhibitory threshold.

You want to maintain a steady, suffocating presence.

Right.

So if a patient has a severe pseudomonas pneumonia, and the bug is sensitive to a beta -lactam like cefapime, the best dosing strategy isn't a massive daily dose.

The optimal method is a 24 -hour continuous IV infusion.

You want a constant drip, drip, drip into the vein so the drug level never dips below the MIC.

It is all about maximizing exposure time.

But there is one more fascinating phenomenon that influences how often we dose.

The post -antibiotic effect, or PAE.

This sounds like a lingering ghost of the drug haunting the bacteria.

It acts very much like one.

Some drugs, particularly those lightning strike eminoglycosides, leave a persistent lingering suppression of bacterial growth even after the blood levels of the drug have fallen completely to zero.

Wait, so the drug isn't even in the blood anymore, but the bacteria are still suppressed?

Exactly.

The bacterial structures are so severely traumatized by that initial high peak that they remain stunted and unable to replicate for hours.

This long post -antibiotic effect is another major reason why aminoglycosides can be effectively given just once a day.

Wow.

So we've navigated the blood -brain barrier, we've weighed the economics, and we've dialed in the exact dosing strategy based on the drug's dynamics.

Now we have to ask, how wide of a net are we casting with these drugs?

Right, because pharmacology classifies these bacteria into groups based on their structures.

Think of them like different specific categories, like gram -positive -cochi or gram -negative -rods.

This brings us to chemotherapeutic spectra.

First you have narrow -spectrum antibiotics.

And they only hit a narrow target, right?

Exactly.

They only hit a single isolated category of bugs.

For instance, the drug isoniazid only attacks mycobacteria, which is the organism that causes tuberculosis.

It leaves everything else in the body completely alone.

Then you step up the ladder to extended -spectrum antibiotics.

A classy example there is ampicillin.

It hits all the standard gram -positive organisms.

But it's been chemically modified in the lab to also reach across the aisle and knock out some of the gram -negative bugs, like E.

coli.

And finally, at the very top of the ladder, you have the broad -spectrum antibiotics, like the tetracyclines.

They cast a massive net.

They kill gram -positives, gram -negatives, anaerobes, spirachettes.

They're indiscriminate killers.

Which makes them incredibly dangerous if misused.

When you use a broad -spectrum drug, you don't just kill the specific infection.

You wipe out the normal, healthy bacterial flora in the patient's gut and respiratory tract.

You are destroying the neighborhood watch.

Yeah, you really are.

And when those good bacteria are wiped out, opportunistic bad actors move into the empty real estate, leading to super infections.

The terrifying example is clostridium difficile, or C.

diff, in the gut, which can take over and cause severe, life -threatening colitis when its natural bacterial competitors are killed off by broad -spectrum antibiotics.

Exactly.

So, to avoid creating those super infections,

the golden rule in pharmacology is always to use a single agent that is most specific to the infecting organism.

Keep the net as narrow as possible.

But you know, if a patient is crashing and incredibly sick,

my instinct as a learner is, if one drug is good, why not mix a bunch together?

Just throw the whole pharmacy at the bug and guarantee a win.

Because in pharmacology, more isn't always better.

Sometimes it actively sabotages the treatment.

Now there are rare cases of synergism where drugs help each other.

For example, treating Enterococcal endocarditis.

If you combine a beta -lactam, which breaks down the outer cell wall with an aminoglycoside, the broken wall acts as an open door, letting the second drug flood into the cell.

But they can also completely interfere with each other, right?

Like, if you combine a bacteriostatic drug like tetracycline with a bactericidal drug you create a disaster.

Let's trace the logic of why that happens.

Tetracycline goes in and stops the bacteria from growing and dividing.

It freezes them.

But penicillin only works by destroying the cell wall of bacteria that are actively multiplying and building new structural walls.

If the bacteria are frozen by the tetracycline, they aren't building anything.

So the first drug completely neutralizes the mechanism of the second drug.

You've given the patient two chemicals, increased their risk of side effects, and achieved less bacterial killing than if you had just used a single drug.

And on top of that interference, throwing too many drugs around just accelerates the rise of antibiotic resistance.

This is the most terrifying reality of this entire field.

The bugs fight back.

They do.

And their evolutionary brilliance is staggering.

The textbook outlines three main mechanisms the bacteria use to survive our drugs.

First is target site modification.

We mentioned streptococcus pneumonia, resisting penicillin earlier.

It does this by physically mutating its own penicillin -binding proteins.

The target changes shape, so the antibiotic can no longer latch onto it.

The bacteria literally changes the locks on the doors.

Exactly.

So our chemical key just doesn't fit anymore.

You got it.

Second is decreased accumulation.

Gram -negative bacteria can actually mutate the structure of their porins, the tiny channels, and their outer membranes so the drug physically can't get inside.

Or even wilder, they develop efflux pumps.

As soon as a drug like tetracycline enters the bacterial cell, this pump acts like a biological bouncer.

It physically grabs the drug molecule and spits it right back out before it can do any damage.

That is incredibly frustrating.

The drug gets in and they just bail it out like water from a sinking boat.

What's a third mechanism?

Enzymatic inactivation.

The bacteria manufacture specific weapons to destroy the drug before it ever reaches its target.

The classic example is beta -lactamase.

This is an enzyme produced by the bacteria that acts like molecular scissors.

It hydrolytically cuts the structural beta -lactam ring of penicillins, rendering the entire drug molecule completely useless.

So the microbes have an entire arsenal to fight back.

But sometimes, the host's own body reacts poorly to the therapy, leading to severe complications that has nothing to do with the bacteria at all.

The most common complication is hypersensitivity, or allergic reactions.

Penicillins, despite targeting cell walls that humans don't even have, are famous for causing immune reactions ranging from simple, itchy hives to full -blown, life -threatening anaphylactic shock.

And sometimes this severe reaction is based simply on how fast you push the drug into the vein.

We mentioned vancomycin earlier.

If you infuse vancomycin into the IV too quickly, the patient can develop Redman syndrome, which is a massive, system -wide histamine release.

Then there are the absolute contraindications.

Right, I was looking at the study questions about Stevens -Johnson syndrome, or SJS.

Yeah, that is a severe, life -threatening sloughing off of the skin and mucous membranes.

It can happen with drugs like sulfamethoxazole, trimethoprim.

And the rule is you never re -challenge them, right?

Not even to try and slowly desensitize them.

Never.

The risk of a figle reaction is simply too high.

You never give them that drug again.

Aside from allergies, high levels of these drugs can cause direct toxicity to human cells.

It's like a toll we pay for using the drug.

What kind of toxicity?

Well, Aminoc lycosides are famous for ototoxicity.

They literally damage the tiny hair cells in your inner ear, causing permanent hearing loss.

Chloramphenicol is highly toxic to your mitochondria and can suppress your bone marrow's ability to make blood cells.

Fluoroquinolones can damage your tendons and cartilage, and tetracyclines, as we discussed, bind to and permanently damage developing bones.

Because of all these risks, hypersensitivity, super infections wiping out the gut, direct toxicity to the ears and bones, the textbook concludes with a very strict warning about

prophylaxis.

We do not just hand out antibiotics to prevent infections willy -nilly.

Absolutely not.

The clinical scenarios where preventative antibiotics are justified are incredibly narrow.

Like what?

We use them for pre -treating patients with a history of rheumatic heart disease to prevent recurrent striptococcal infections.

We use them for patients with artificial heart valves undergoing dental work to stop bacteria from the mouth from entering the blood and seeding the artificial valve.

We also use them for individuals in close contact with patients who have severe, highly contagious diseases like active tuberculosis or meningitis.

And finally, we use them right prior to certain surgical procedures to prevent post -operative infections.

And that is pretty much the entire list.

We protect the drugs by limiting their use.

Which brings us to the ultimate summary of everything we've covered today.

If you look at figure 28 .9, a diagram of a single bacterial fortress, you can map out exactly where all these chemical weapons strike.

It's a great visual summary.

You have the cell wall inhibitors, like the beta -lacoms and vancomycin, attacking the outer perimeter.

Deep inside the cell, you have the protein synthesis inhibitors, the macrolides, aminoglycosides, and tetracyclines jamming up the ribosomes so the bacteria can't build proteins.

And right in the center, you have the fluoroquinolones disrupting the replication of the DNA itself.

If we connect this to the bigger picture, studying pharmacology isn't just about memorizing a disjointed list of drug names and side effects.

It is about understanding this elegant microscopic tug of war between human physiology and bacterial survival.

We've tracked the drug from the initial lab culture, analyzed the physics of how it sneaks across the blood -brain barrier, evaluated its financial cost, dialed in the perfect continuous 5V drip to outsmart its kinetics, and mapped out how it can accidentally damage the host's ears or bones.

Every single decision a clinician makes is balancing that scale of selective toxicity.

It is a delicate, high -stakes balance every time a prescription pad is signed.

And I want to leave you, our listener, with a final provocative thought.

We talked about how fast the bugs are adapting.

You've only new efflux pumps to physically spit drugs out, and molecular scissors like beta -lactamase to chew them up.

If their defense mechanisms are adapting this incredibly fast to everything we invent, how will our therapeutic strategies have to evolve in the next decade to keep up with them?

Because the burglar is already learning how to wear a gas mask.

It is the defining medical arms race of our time.

It truly is.

Keep studying hard, trust the physiology behind the drugs, and thank you for listening from the Last Minute Lecture team.